In cutaneous polyarteritis nodosa (CPAN), less aggressive treatments can be selected, because CPAN is not associated with life-threatening or progressive outcomes. Although patients with a recurrent clinical course may require additional immunosuppressive therapies, no pretreatment factors associated with a worse prognosis in CPAN have been reported. 
RESULTS
The 21 patients included 5 males and 16 females with a median age of 49 years (range, 11-74 years) at diagnosis. The median follow-up was 42 months (range, 8-374 months). Pretreatment cutaneous ulcer was significantly associated with relapse between the 2 groups (0 of 11 in the nonrelapse group vs 4 of 10 in the relapse group; χ 2 1 = 4.67; P < .05). In the laboratory test results, significantly higher mean (SD) values were observed in the relapse group for C-reactive protein level (0.23 [2. 00] vs 6.03 [3.10] CONCLUSIONS AND RELEVANCE Pretreatment status of cutaneous ulcer, the serum C-reactive protein level, the blood ANC, the neutrophil-to-lymphocyte ratio, and the systemic immune-inflammation index are associated with a worse prognosis in CPAN. C utaneous polyarteritis nodosa (CPAN) is a rare form of necrotizing vasculitis involving small and medium arteries that affects skin preferentially. [1] [2] [3] [4] Based on the Chapel Hill Consensus Conference of 2012 on the classification of the vasculitides, CPAN has been reclassified as cutaneous arteritis in single-organ vasculitis. 5 The clinical course of CPAN is usually not life-threatening or progressive. Occasionally, extracutaneous symptoms such as malaise, arthralgia, and neuropathy may occur. 3, 6 Patients with CPAN and a recurrent clinical course may require additional immunosuppressive therapy after initial treatment. Prognostic markers of CPAN relapse have been undetermined. We conducted the present retrospective analysis to investigate and identify such potential markers.
Methods

Patients
Thirty patients with CPAN who were treated at Okayama University Hospital, Okayama, Japan, from October 1, 2001, through April 30, 2017, were examined. Histopathologic diagnosis consisted of necrotizing vasculitis involving small and medium arteries in the deep dermal to subcutaneous fat of the affected skin. To rule out systemic disease, we checked laboratory findings, including levels of antinuclear antibody, antineutrophil cytoplasmic antibody, and complement. Computed tomography, visceral angiography, and endoscopy of the gastrointestinal tract were also examined, when indicated. Of the 30 patients, 21 were eligible for the study and enrolled ( Table 1) . This study was approved by the institutional review board of Okayama University Hospital, and all patients provided written informed consent for their data to be used, in accordance with the 1975 Declaration of Helsinki.
We used the medical records of the 21 patients to determine each patient's sex, age at diagnosis, affected anatomical sites, the type and extent of skin lesions, laboratory data, initial therapies, duration of follow-up, and current status. We also examined the following pretreatment blood indices: the neutrophil-to-lymphocyte ratio (NLR), plateletto-lymphocyte ratio, systemic immune-inflammation index (SII; calculated as the product of the neutrophil count and the platelet count divided by the lymphocyte count 7 ), and red cell distribution width.
In the present study, we defined relapse as the first reoccurrence or new onset of cutaneous disease that required further escalation of treatment with prednisone at a dosage of more than 20 mg/d and/or additional use of immunosuppressants observed more than 6 months after the initial therapy. This definition was based on the proposed European League Against Rheumatism recommendations for clinical studies in 2007. 8 
Statistical Analysis
The statistic al analyses were performed using the Mann-Whitney test and the Pearson χ 2 test for the comparisons of clinical and examination variables between the groups with and without relapse, with a significance level of P < .05.
The cumulative relapse rate was calculated based on the time from the date of the start of the initial therapy to the date of the first relapse as described above. We estimated the 2-year cumulative relapse rate between groups with blood ANC above and below the median using the Kaplan-Meier method; statistical analyses were performed with SPSS version 20.0 (IBM Corp). We used the log-rank test in univariate analyses to estimate the 2-year cumulative relapse rates.
Results
The clinical characteristics of the 21 patients are summarized in Table 1 . The 5 male and 16 female patients (M:F ratio, 0.3) had a median age of 49 years (range, 11-74 years) at diagnosis. The median observation period was 42 months (range, 8-374 months). The 11 patients in the nonrelapse group (M:F ratio, 0.1) had a median age of 48 years (range, 14-67 years), and the 10 patients in the relapse group (M:F ratio, 0.7) had a median age of 51 years (range, 11-65 years).
The clinical manifestations of the patients included indurated erythema in 19 (90%), livedo in 18 (86%), purpura in 5 (24%), and cutaneous ulcer in 4 (19%) ( Table 1 ). The lower limbs were mainly affected in 19 patients (90%); upper limbs, 11 (52%); and the trunk, 5 cases (24%). A significant betweengroup difference was detected only in cutaneous ulcers (0 of 11 in the nonrelapse group vs 4 of 10 in the relapse group; χ 2 1 = 4.67; P = .04). Eleven patients (52%) had neuralgia localized to the affected skin, and 10 (48%) had arthralgia; the rates between groups were not significantly different ( ; P = .007) ( Table 2 ). The patients' initial therapies included prednisone in 15 (71%), cyclophosphamide in 2 (10%), azathioprine sodium in
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Clinical and Laboratory Markers of Relapse in Cutaneous Polyarteritis Nodosa 1 (5%), nonsteroidal anti-inflammatory drugs (NSAIDs) in 2 (10%), colchicine in 1 (5%), antithrombotic agents in 11 (52%), and diaminodiphenyl sulfone in 1 (5%). Three patients (14%) died of CPAN-unrelated causes. None had experienced progression to the systemic form during the observation period. The estimated 2-year cumulative relapse rate was significantly high in the patients with blood ANC above 4.9 × 10 3 /μL compared with those with blood ANC of 4.9 × 10 3 /μL or less (9 of 10 [90%] vs 2 of 11 [18%]; 95% CI, 6%-72%) (Figure) .
Discussion
Female predominance in CPAN was reported in several studies, 1,2,4,6 as well as in our cohort. Rarely, CPAN progresses to a systemic form. 9 In our cohort, no patient experienced disease-specific death or progression to the systemic form during the follow-up period. Peripheral polyneuropathy was observed in 11 patients (52%); arthralgia was observed in 10 (48%). Without exception, these symptoms were localized to the CPAN-affected skin. No patients had mononeuritis multiplex.
Cutaneous polyarteritis nodosa is commonly treated with antithrombotic therapies, nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, diaminodiphenyl sulfone, or warfarin potassium. 1, 2, 4, 6, 10 Patients with CPAN refractory to conservative treatments may require more intensive therapeutic approaches. In our series, 16 patients (76%) were initially treated with oral prednisone, and 3 (14%) were treated with immunosuppressants. Monotherapy with antithrombotic agents (n = 2) and NSAIDs (n = 2) showed beneficial effects in 4 patients (19%). Our analysis indicates that the clinical status of pretreatment cutaneous ulcer may be associated with a worse prognosis for CPAN involved in relapse. Other clinical symptoms such as neuropathy and arthropathy were not associated with relapse in this retrospective analysis.
Since 2005, pretreatment blood indices such as the NLR, platelet-to-lymphocyte ratio, and SII were developed as clinically useful markers reflecting the general conditions of host inflammatory and immunity. 7, [11] [12] [13] [14] They are variously used as prognostic predictors for cancer, metabolic syndrome, and several inflammatory conditions and for evaluating cardiovascular risk and events. In the present study, the elevated serum CRP level, blood ANC, NLR, and SII may also be associated with worse prognosis. The estimated 2-year cumulative relapse rate was significantly high in our patients with a blood ANC of above 4.9 × 10
